About half of the melanoma patients harbor activating mutation in oncogenes involved in the mitogen-activated protein kinase (MAPK) pathway, e.g., BRAF or NRAS and/or constitutive activation of the cell cycle modulating phosphoinositide 3-kinase (PI3K) signaling pathway. This evidence concerns the gene BRAF and melanoma.